...
首页> 外文期刊>Alzheimer’s & dementia: the journal of the Alzheimer’s Association >Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative
【24h】

Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative

机译:了解疾病进展和改善阿尔茨海默病的疾病临床试验:最近从阿尔茨海默病神经影像症的亮点

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI is a multisite, longitudinal, observational study that has collected many biomarkers since 2004. Recent publications highlight the multifactorial nature of late-onset AD. We discuss selected topics that provide insights into AD progression and outline how this knowledge may improve clinical trials.
机译:简介:阿尔茨海默病的整体目标神经影像倡议(ADNI)是验证阿尔茨海默病(AD)临床试验的生物标志物。 Adni是自2004年以来收集了许多生物标志物的多路,纵向,观测研究。最近的出版物突出了后期广告的多因素性质。 我们讨论所选主题,提供对广告进展的见解,并概述了这种知识如何改善临床试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号